Wileman, Vari http://orcid.org/0000-0002-9673-8047
McGuinness, Serena
Sweeney, Louise
Norton, Christine
Miller, Laura
Stagg, Imogen
O’Carroll, Ronan
Moss-Morris, Rona
Funding for this research was provided by:
National Institute for Health and Care Research (RP-PG-0216-20001)
Article History
Received: 11 December 2023
Accepted: 18 June 2024
First Online: 12 July 2024
Declarations
:
: Favourable ethical opinion was granted for the trial and the risk assessment protocol by a Research Ethics Committee (London—Surrey Research Ethics Committee/19/LO/0750). All participants provided written informed consent. This study was conducted in line with relevant guidance, regulations, and the ethical approvals granted to this study and in accordance with the Declaration of Helsinki.
: Informed consent for publication was received from all participants before their commencement in the study.
: CN declares the following conflicts of interest: speaker fees from: Janssen, WebMD, Medscape, Merck Pharmaceutical; Tillotts Pharms UK. Pfizer advisory board. RMM is a beneficiary of a licence agreement signed between King’s College London and Mahana Therapeutics for a digital cognitive behavioural therapy for an irritable bowel syndrome product. RMM receives personal fees from Mahana Therapeutics for scientific advisory work and from other universities and hospital trusts for cognitive behavioural therapy training in irritable bowel syndrome. Co-authors declare no further competing interests.